Navigation Links
Tepha Partner Launches Novel Monofilament Absorbable Suture Utilizing Tepha's Proprietary Biomaterial
Date:5/1/2009

Tepha Corporate Partner, Aesculap AG, Introduces MonoMax(R) Monofilament Suture at the German Surgical Congress in Munich following Receipt of CE Mark

LEXINGTON, Mass., May 1 /PRNewswire/ -- Tepha, Inc., a developer of medical devices announced today that its corporate partner, Aesculap AG, has received a CE Mark and is launching its MonoMax monofilament absorbable suture for general surgical indications in Europe. The product is made with TephaFLEX(R) fiber, one of Tepha's new class of novel resorbable polyhydroxyalkanoate (PHA) polymers. The Tepha PHA polymer family is a product of the Company's patented recombinant DNA technology, which allows the engineering of resorbable medical devices with mechanical and biologic properties that are matched to specific tissue repair and replacement applications. MonoMax monofilament suture has longer strength retention than currently marketed resorbable sutures, and is more flexible. The product joins a strong portfolio of suture products from B. Braun Aesculap, currently at number two in share of the European suture market.

Miguel Pablo, Vice President Marketing & Sales and Regulatory Affairs Closure Technologies for the Aesculap Division stated, "B. Braun Aesculap is excited to be introducing this new technology into the European market for wound closure. We have been working with Tepha for several years to develop the MonoMax product line and believe Tepha's unique biomaterial will provide benefits to our customers and to their patients".

A clinical trial, the Multi-Center Study to Evaluate the Safety and Efficacy of Aesculap MonoMax for Abdominal Wall Closure or (ISSAAC), was recently concluded with positive results. The trial enrolled approximately 150 patients who were followed for twelve months after surgery. In the trial, the MonoMax suture was used for a continuous all-layer (except skin) suture to close abdominal wall after midline incision
'/>"/>

SOURCE Tepha, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dr Stephan Rietiker Joins BioCeramic Therapeutics
2. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
3. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
4. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
5. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
6. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
7. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
8. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
9. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
10. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
11. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Involution Studios , a ... a new infographic, Understanding Ebola . The ... designed, easy to follow informative tool for anyone wanting ... symptoms and prevention. , "As the news has spread ... Ebola outbreak represents not only a healthcare crisis with ...
(Date:10/22/2014)... October 22, 2014 Physicians Choice ... cardiovascular pharmacogenetics menu, which enables healthcare providers to ... With PCLS’s evidence-based results, healthcare providers are better ... their therapy, while minimizing risks for adverse drug ... according to the FDA [1] more than 2.2 ...
(Date:10/22/2014)... 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) – ... people worldwide are living with diabetes, with  that number ... The global market for diabetes treatments is approximately $500 ... worldwide died from pancreatic cancer.  Pancreatic cancer is the ... in the United States , and ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... Inc. (OTC: MSEL) operating under its principal brand ... of visual communications and brand imaging solutions, was awarded " ... 9th Annual American Business Awards Ceremony, in recognition of its ... solid results, despite prevailing economic turbulence. The American ...
... 2011 Amylin Pharmaceuticals, Inc. (Nasdaq: ... present data for its two first-in-class diabetes drugs, ... and its investigational diabetes drug candidates BYDUREON™ (exenatide ... at the 71st Scientific Sessions of the American ...
... 2011 Scientists Drs. Samuel and Elenore Bogoch of BioRadar ... in Replikin Counts of the EHEC lethal strains of E. ... of E. Coli have been studied in laboratories in Germany ... in the public databases. Replikins are subsequences of the genome ...
Cached Biology Technology:Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 2Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 3Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 4Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 5Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 2Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 3Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 4Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 5Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 6Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 7Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 8Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 2Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 3
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
(Date:10/17/2014)... news release is available in German . ... millions of sperms every day in order to reproduce? And ... are the topic of the latest issue of the research ... 2014). The evolutionary biologist Steven Ramm from Bielefeld University Bielefeld ... it is not unusual for a female to copulate with ...
(Date:10/16/2014)... body. Battles are won, lost or sometimes end ... as tumor dormancy—can last up to 25 years ... poorly understood. , A new computational model ... Professor of Chemistry at Princeton University, may help ... switch to a malignant state. Published today in ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
... top technological universities have come together to form ... brings together these leading engineering-based universities in the ... address global societal issues is through the joint ... top class research in science and technology. ...
... Scientists have completed the first study of microbes that ... the Gulf of Mexico, where conditions may resemble those ... was partially funded by the National Science Foundation (NSF), ... vents spew mud, oil, brine and gases that support ...
... Outreach efforts by the Translational Genomics Research Institute (TGen) ... the second year, TGen will help organize a cancer ... The 2nd annual Fort Defiance Cancer Awareness and Advocacy ... 8:30 a.m.-5 p.m. July 18 at the Navajo Nation ...
Cached Biology News:Global alliance of leading technological universities to address global societal issues 2Better living through chemistry 2Better living through chemistry 3TGen helps promote cancer awareness for vast Navajo Nation 2TGen helps promote cancer awareness for vast Navajo Nation 3
...
Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Acetyl CoA Carboxylase Antibody...
mu Opioid Receptor splice variant Immunogen: Synthetic peptide corresponding to residues K S C M D R G M R N L L P D D G P R Q E of Mu Opioid Receptor. Storage: -20 C, Avoid Freeze/Thaw Cycle...
Biology Products: